Radioactive iodine (RAI)-refractory/resistant papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), or Hürthle cell thyroid cancer (HTC). The patient’s disease must have progressed on one line of VEGFR-targeted therapy (including, but not limited to, sorafenib, sunitinib, vandetanib, pazopanib, or lenvatinib). This evidence concerns the gene KDR and thyroid gland papillary carcinoma.